Article Title,Year,Volume,Issue,Page Range,Author
Effect of consumer reporting on signal detection: using disproportionality analysis,2007,6,6,705-712,Hammond
Benefits and risks of using antidepressants in children and adolescents,2008,7,1,9-27,Bailly
Clinical consequences of polypharmacy in elderly: expect the unexpected think the unthinkable,2007,6,6,695-704,Salazar
Depression as a side effect of the contraceptive pill,2007,6,4,371-374,Kulkarni
Acetaminophen safety and hepatotoxicity--where do we go from here?,2007,6,4,341-355,Amar
Adverse effects of antiepileptic drugs on bone mineral density in children,2007,6,3,267-278,Vestergaard
The adverse effects of antiepileptic drugs in children,2007,6,3,251-265,Kothare
Antidepressants use in pediatric populations,2008,7,3,223-225,Gören
Varenicline and suicidality: a new era in medication safety surveillance,2008,7,5,511-514,McIntyre
Suicidality and montelukast,2009,8,3,273-282,Postolache
Safety and side effect profile of fluoxetine,2004,3,5,495-504,Wernicke
Antidepressant up-titration: pharmacological and psychological considerations,2012,11,5,685-688,Torta
Safety and risk communication to patients,2006,5,6,747-750,Thürmann
Clinical and causality assessment in herbal hepatotoxicity,2013,12,3,339-366,Schulze
Safety of benzodiazepines in the geriatric population,2004,3,5,485-493,Madhusoodanan
Suicide and epilepsy: do antiepileptic drugs increase the risk?,2015,14,4,553-558,Sander
Reducing the harm of opioid overdose with the safe use of naloxone : a pharmacologic review,2015,14,7,1137-1146,Nelson
Renal risk associated with sodium phosphate medication: safe in healthy individuals potentially dangerous in others,2015,14,7,1097-1110,Hoffmanová
Opioid risk assessment in palliative medicine,2015,14,7,1023-1033,Krashin
Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving,2015,15,1,89-98,Yanai
Adverse neuropsychiatric effects of antimalarial drugs,2016,15,7,903-910,Grabias
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons,2016,15,10,1301-1312,Mendes
The risks associated with prenatal antidepressant exposure: time for a precision medicine approach,2017,16,8,915-921,Pedersen
Potential strategies to combat the opioid crisis,2019,18,3,211-217,Mercadante
How do safety warnings on medicines affect prescribing?,2022,ePub,ePub,ePub,Dormuth
Balancing the risk of stroke and bleeding in atrial fibrillation patients with a history of falls,2023,ePub,ePub,ePub,Lip
Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions,2023,22,1,71-79,Martín Arias
Anti-tuberculosis drugs adverse reactions: A review of the Iranian literature,2014,13,7,875-891,Javadi
Do we need to worry about mycophenolate overdose?,2014,13,5,521-524,Filler
The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis,2022,21,6,841-852,McIntyre
Psychiatric symptoms associated with ephedra use,2005,4,5,879-884,Shekelle
Adverse reactions to duloxetine in depression,2011,10,6,839-850,Czobor
Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications,2011,10,6,913-934,Hamed
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS),2024,23,1,47-55,McIntyre
Adverse effects associated with antipsychotic use in older adults,2024,ePub,ePub,ePub,Aparasu
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects,2024,ePub,ePub,ePub,Zhang
Assessing suicide risk in chronic pain management: a narrative review across drug classes,2024,ePub,ePub,ePub,Candido